Life Technologies (NASDAQ: [[ticker:LIFE]]) the Carlsbad, CA-based maker of gene sequencing instruments and lab supplies, said today it is joining an effort with two partners to sequence the genomes of 14 women with an aggressive form of breast cancer. The partnership, with the Phoenix-based Translational Genomics Research Institute and U.S. Oncology in Woodands, TX, will sequence the genomes of patients with what is known as “triple-negative” breast cancer, which about one-fifth of women with the disease have, and which doesn’t respond to targeted therapies like Roche’s trastuzumab (Herceptin).
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
